Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Sensitive Mutation”

43 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 43 results

Testing effectiveness (Phase 2)UnknownNCT04882345
What this trial is testing

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Who this might be right for
Lung CancerEGFR Gene Mutation
Shanghai Chest Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT05284539
What this trial is testing

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 760
Testing effectiveness (Phase 2)UnknownNCT03457337
What this trial is testing

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Who this might be right for
Advanced NSCLC With EGFR Mutation
Henan Cancer Hospital 200
Testing effectiveness (Phase 2)UnknownNCT03396185
What this trial is testing

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Who this might be right for
EGFR Gene MutationNon Small Cell Lung Cancer Stage IIIANon Small Cell Lung Cancer Stage IIIB
Betta Pharmaceuticals Co., Ltd. 30
Early research (Phase 1)Study completedNCT00903734
What this trial is testing

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 16
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Testing effectiveness (Phase 2)Looking for participantsNCT06652048
What this trial is testing

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Who this might be right for
Non-Small Cell Lung Cancer
Jialei Wang 60
Large-scale testing (Phase 3)Looking for participantsNCT06043973
What this trial is testing

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Who this might be right for
Advanced Non-small Cell Lung Cancer
Qianfoshan Hospital 98
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06530719
What this trial is testing

Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

Who this might be right for
Lung NeoplasmsLung Cancer, Nonsmall Cell
Jin Ying 54
Large-scale testing (Phase 3)UnknownNCT04797806
What this trial is testing

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 206
Testing effectiveness (Phase 2)Looking for participantsNCT06348927
What this trial is testing

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 52
Testing effectiveness (Phase 2)Study completedNCT03736837
What this trial is testing

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06182761
What this trial is testing

Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Shanghai Zhongshan Hospital 45
Not applicableUnknownNCT03381430
What this trial is testing

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Who this might be right for
Lung Cancer
Qilu Pharmaceutical Co., Ltd. 50
Testing effectiveness (Phase 2)Looking for participantsNCT06355609
What this trial is testing

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT06945705
What this trial is testing

A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis

Who this might be right for
NSCLC
Henan Cancer Hospital 146
Not applicableLooking for participantsNCT06481566
What this trial is testing

Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial

Who this might be right for
Non-small Cell Lung Cancer
Chongqing University Cancer Hospital 30
Not applicableUnknownNCT01775943
What this trial is testing

Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

Who this might be right for
Lung Neoplasms
Ulsan University Hospital 90
Early research (Phase 1)Study completedNCT04991480
What this trial is testing

ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced CancerMetastatic CancerBreast Cancer
Artios Pharma Ltd 93
Early research (Phase 1)Study completedNCT02163733
What this trial is testing

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 38
Load More Results